250 related articles for article (PubMed ID: 9155515)
1. Is screening for prostate cancer the current gold standard?--"no".
Kramer BS; Gohagan JK; Prorok PC
Eur J Cancer; 1997 Mar; 33(3):348-53. PubMed ID: 9155515
[No Abstract] [Full Text] [Related]
2. Is screening for prostate cancer the current gold standard?--"yes".
Lange PH
Eur J Cancer; 1997 Mar; 33(3):354-6. PubMed ID: 9155516
[No Abstract] [Full Text] [Related]
3. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
4. Prostate cancer: enthusiasm for screening.
Kaye KW
Med J Aust; 1995 May; 162(10):540-1. PubMed ID: 7539884
[No Abstract] [Full Text] [Related]
5. Efficacy vs effectiveness in prostate-specific antigen screening.
Albertsen PC
J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
[No Abstract] [Full Text] [Related]
6. Screening for prostate cancer - will we ever know?
Adolfsson J
Acta Oncol; 2010 Apr; 49(3):275-7. PubMed ID: 20397764
[No Abstract] [Full Text] [Related]
7. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Belpomme D; Irigaray P
J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
[No Abstract] [Full Text] [Related]
8. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
Hamilton RJ; Platz EA; Freedland SJ
J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
[No Abstract] [Full Text] [Related]
9. How valuable is prostate-specific antigen screening?
Handler S
Minn Med; 1996 Jun; 79(6):2. PubMed ID: 8692130
[No Abstract] [Full Text] [Related]
10. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
Zhao XJ; Kong XB; Wang WH
Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
[TBL] [Abstract][Full Text] [Related]
11. Prostatic specific antigen in prostate cancer.
Wozniak-Petrofsky J
Urol Nurs; 1992 Sep; 12(3):104-5. PubMed ID: 1382317
[No Abstract] [Full Text] [Related]
12. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
13. [Mass screening for prostate cancer will have to wait. The scientific basis insufficient, more efficient markers necessary].
Damber JE
Lakartidningen; 2003 Sep; 100(38):2916-8, 2921. PubMed ID: 14558209
[No Abstract] [Full Text] [Related]
14. Prostate cancer: screening and treatment options.
Horger DC; Clarke HS
J S C Med Assoc; 2003 Apr; 99(4):85-7. PubMed ID: 12762154
[No Abstract] [Full Text] [Related]
15. [Mass screening for prostate cancer in Nagano].
Ishizuka O; Satoh T; Kobayashi S; Nishizawa O
Hinyokika Kiyo; 2001 Nov; 47(11):769-72. PubMed ID: 11771167
[TBL] [Abstract][Full Text] [Related]
16. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Rosser CJ; Parker A
J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
[No Abstract] [Full Text] [Related]
17. Mass screening for prostate cancer. The Swedish Council on Technology Assessment in Health Care.
Int J Cancer Suppl; 1996; 9():1-72. PubMed ID: 8982323
[No Abstract] [Full Text] [Related]
18. [The prostate specific antigen: what can we learn from the American experience?].
Zhao XJ
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3313-5. PubMed ID: 16409833
[No Abstract] [Full Text] [Related]
19. Application of prostate-specific antigen in prostate cancer.
Liang SL
MLO Med Lab Obs; 2008 Oct; 40(10):54, 56-7. PubMed ID: 18988558
[No Abstract] [Full Text] [Related]
20. Prostate cancer: screening and early detection.
Tariman JD
Adv Nurse Pract; 2006 Sep; 14(9):20. PubMed ID: 16972436
[No Abstract] [Full Text] [Related]
[Next] [New Search]
